Andrew J Armstrong


Affiliation: Duke University Medical Center
Country: USA


  1. Zhang T, George D, Armstrong A. Precision medicine approaches when prostate cancer Akts up. Clin Cancer Res. 2018;: pubmed publisher
    ..These data revive the rationale for targeting PTEN loss in prostate cancer. ..
  2. Zhang T, Dhawan M, Healy P, George D, Harrison M, Oldan J, et al. Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2015;13:392-9 pubmed publisher
    ..These data might inform the complex treatment decisions after AA treatment. ..
  3. Zhang T, Armstrong A. Docetaxel Resistance in Prostate Cancer: Taking It Up a Notch. Clin Cancer Res. 2015;21:4505-7 pubmed publisher
  4. Brown L, Sonpavde G, Armstrong A. Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer?. Prostate Cancer Prostatic Dis. 2018;21:419-430 pubmed publisher
    ..These data support considering RECIST response as a supportive but not sole endpoint in phase 2 trials to support launching phase 3 trials. ..
  5. Armstrong A, Kaboteh R, Carducci M, Damber J, Stadler W, Hansen M, et al. Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC). Urol Oncol. 2014;32:1308-16 pubmed publisher
    ..A delay in objective radiographic bone scan progression with TASQ is suggested; prospective evaluation of BSI progression and response criteria in phase 3 trials of men with mCRPC is warranted. ..
  6. Bitting R, Healy P, Halabi S, George D, Goodin M, Armstrong A. Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer. Urol Oncol. 2015;33:110.e1-9 pubmed publisher
    ..CTC enumeration appears to be prognostic in men with mCRPC and describes a phenotype of hematogenous dissemination that cannot be predicted based on standard clinical and laboratory assessments. ..
  7. request reprint
    Armstrong A, Garrett Mayer E, Yang Y, de Wit R, Tannock I, Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res. 2007;13:6396-403 pubmed
    ..External prospective validation may support the wider use of this prognostic baseline model for men with HRPC treated with chemotherapy. ..
  8. Armstrong A, Tannock I, de Wit R, George D, Eisenberger M, Halabi S. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer. 2010;46:517-25 pubmed publisher
    ..Prospective validation of this classification system is needed. ..
  9. request reprint
    Armstrong A, Garrett Mayer E, Ou Yang Y, Carducci M, Tannock I, de Wit R, et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2007;25:3965-70 pubmed
    ..However, given the wide CIs around the estimate of this moderate surrogate effect, overall survival should remain the preferred end point for phase III trials of cytotoxic agents in HRPC. ..

More Information


  1. Armstrong A, Febbo P. Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature. Oncologist. 2009;14:816-27 pubmed publisher
  2. Armstrong A. New treatments for men with castration-resistant prostate cancer: can we move from small steps to giant leaps?. Eur Urol. 2014;65:300-2 pubmed publisher
  3. Armstrong A, Halabi S, Eisen T, Broderick S, Stadler W, Jones R, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016;17:378-88 pubmed publisher
    ..Future trials of novel agents should account for heterogeneity in disease outcomes based on genetic, histological, and prognostic factors. Novartis and Pfizer. ..
  4. Austin R, Huang T, Wu M, Armstrong A, Zhang T. Clinical utility of non-EpCAM based circulating tumor cell assays. Adv Drug Deliv Rev. 2018;125:132-142 pubmed publisher
    ..In addition, we address challenges that remain for the clinical translation of these platforms. ..
  5. Armstrong A, Eisenberger M, Halabi S, Oudard S, Nanus D, Petrylak D, et al. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol. 2012;61:549-59 pubmed publisher
    ..A greater understanding of biomarkers in CRPC permits a more personalized approach to care that maximizes benefit and minimizes harm and can inform clinical trials tailored to men most likely to derive benefit. ..
  6. Armstrong A, Marengo M, Oltean S, Kemeny G, Bitting R, Turnbull J, et al. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res. 2011;9:997-1007 pubmed publisher
  7. Armstrong A, George D, Halabi S. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. J Clin Oncol. 2012;30:3402-7 pubmed publisher
    ..Further investigation of the predictive role of LDH as a measure of benefit with PI3K/TORC1 pathway inhibition in other RCC risk groups and other tumor types is warranted. ..
  8. Zhang T, Boominathan R, Foulk B, Rao C, Kemeny G, Strickler J, et al. Development of a Novel c-MET-Based CTC Detection Platform. Mol Cancer Res. 2016;14:539-47 pubmed publisher
    ..This study developed a novel c-MET CTC assay for detecting c-MET CTCs in patients with MET amplification and warrants further investigation to determine its clinical applicability. Mol Cancer Res; 14(6); 539-47. ©2016 AACR. ..
  9. Gupta S, Li J, Kemeny G, Bitting R, Beaver J, Somarelli J, et al. Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2017;23:1346-1357 pubmed publisher
    ..i>Clin Cancer Res; 23(5); 1346-57. ©2016 AACR. ..
  10. Armstrong A, Halabi S, Healy P, Alumkal J, Winters C, Kephart J, et al. Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer. Eur J Cancer. 2017;81:228-236 pubmed publisher
    ..Future studies of PI3K pathway inhibitors with concurrent enzalutamide should develop optimal dosing and focus on selected patients more likely to benefit. ..
  11. Humeniuk M, Gupta R, Healy P, McNamara M, Ramalingam S, Harrison M, et al. Platinum sensitivity in metastatic prostate cancer: does histology matter?. Prostate Cancer Prostatic Dis. 2018;21:92-99 pubmed publisher
    ..Molecular predictors, such as germline or somatic mutations in DNA repair enzymes, should be evaluated for platinum responsiveness. ..